An integrated analysis of a relevant set of 14 autoantibody specificities and a multiplex 12-cytokine Luminex data set in a combined set of 93 samples consisting of three independent cohorts (a US-based Autoimmune Biomarkers Collaborative Network [ABCoN] cohort [n = 29], a Swedish cohort [n = 43], and a Japanese cohort [n = 21]) showed superior differentiation of responders and non-responders.
An integrated analysis of this data set was greatly facilitated by all plants being genotyped with the same intermediate-frequency SNPs chosen to be maximally informative across the 17 populations.
Before integrated analysis, Affymetrix expression probe sets were matched with Agilent aCGH probes using the hg17/NCBI database.
The integrated analysis of these different data sets ensures that findings from one particular data set are reinforced by another, thereby minimizing potential false-positive and -negative findings that might emerge when these data sets are analyzed in isolation [ 58, 59].
These experts were generally qualified only on the basis of past design experience and typically had access to a limited set of integrated analysis tools.
A global, integrated analysis of the entire data set, with a focus on individual differences, was not possible until the completion of data collection for all subjects in all tasks.
A variety of sequence analysis and visualization tools are available in the RoBuST web interface for the integrated analysis of these diverse data sets.
Performing concomitant transcriptomics analysis in samples subjected to lipidomic profiling enables the integrated analysis of these complementary data sets to derive mechanistic information regarding the toxicological meaning of lipid alterations.
The final sample set in the integrated analysis included the four most commonly seen histological subtypes of ovarian cancer – serous (n = 37), endometrioid (n = 14), mucinous (n = 7) and clear cell (n = 9).
Hence, the robust data set of the integrated analysis corroborates the clinical and neuroradiological findings from the individual studies, including the finding from DEFINE that DMF therapy significantly reduces the risk of confirmed disability progression.
